Tokyo Tape
Sign in
← Kaken Pharmaceutical

Quarterly report · Q3

4521.TEDINET S100SS78
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥54.7bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥73.0bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥55.6bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥8.9bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥12.4bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥9.3bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥8.7bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥13.0bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥9.2bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥12.6bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥6.7bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥5.4bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥9.1bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥6.7bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥9.1bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥168.3bnat 2023-12-31Cons.Assets
Total assets¥166.3bnat 2023-03-31Cons.Assets
Total assets¥167.8bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥28.2bnat 2023-12-31Cons.Liabilities
Total liabilities¥29.5bnat 2023-03-31Cons.Liabilities
Net assets / equity¥140.1bnat 2023-12-31Cons.Net assets
Net assets / equity¥136.8bnat 2023-03-31Cons.Net assets
Net assets / equity¥140.7bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥51.5bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥59.6bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥177.12023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.852023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥144.82022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥243.312022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥84.992022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio83.2%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio81.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio83.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q3r_E00935-000Medicinereportable segmentrevenue2023-04-01 → 2023-12-31¥52.9bn
jpcrp040300-q3r_E00935-000Medicinereportable segmentrevenue external2023-04-01 → 2023-12-31¥52.9bn
jpcrp040300-q3r_E00935-000Medicinereportable segmentsegment profit2023-04-01 → 2023-12-31¥7.9bn
jpcrp040300-q3r_E00935-000Real Estatereportable segmentrevenue2023-04-01 → 2023-12-31¥1.8bn
jpcrp040300-q3r_E00935-000Real Estatereportable segmentrevenue external2023-04-01 → 2023-12-31¥1.8bn
jpcrp040300-q3r_E00935-000Real Estatereportable segmentsegment profit2023-04-01 → 2023-12-31¥1.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥54.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥54.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥8.9bn
jpcrp040300-q3r_E00935-000Medicinereportable segmentrevenue2022-04-01 → 2022-12-31¥53.8bn
jpcrp040300-q3r_E00935-000Medicinereportable segmentrevenue external2022-04-01 → 2022-12-31¥53.8bn
jpcrp040300-q3r_E00935-000Medicinereportable segmentsegment profit2022-04-01 → 2022-12-31¥11.4bn
jpcrp040300-q3r_E00935-000Real Estatereportable segmentrevenue2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E00935-000Real Estatereportable segmentrevenue external2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E00935-000Real Estatereportable segmentsegment profit2022-04-01 → 2022-12-31¥960m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥55.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥55.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥12.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 380
ItemContextValueUnit
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration55573000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E00935-000MedicineReportableSegmentsMember11433000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E00935-000RealEstateReportableSegmentsMember960000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember12394000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember－JPY
Operating incomePrior1YTDDuration12394000000JPY
Net sales of finished goods and merchandiseCurrentYTDDuration_jpcrp040300-q3r_E00935-000MedicineReportableSegmentsMember51645000000JPY
Net sales of finished goods and merchandiseCurrentYTDDuration_jpcrp040300-q3r_E00935-000RealEstateReportableSegmentsMember－JPY
Net sales of finished goods and merchandiseCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember51645000000JPY
Net sales of finished goods and merchandiseCurrentYTDDuration_ReconcilingItemsMember－JPY
Net sales of finished goods and merchandiseCurrentYTDDuration51645000000JPY
RoyaltyCurrentYTDDuration_jpcrp040300-q3r_E00935-000MedicineReportableSegmentsMember1219000000JPY
RoyaltyCurrentYTDDuration_jpcrp040300-q3r_E00935-000RealEstateReportableSegmentsMember－JPY
RoyaltyCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1219000000JPY
RoyaltyCurrentYTDDuration_ReconcilingItemsMember－JPY
RoyaltyCurrentYTDDuration1219000000JPY
Other incomeCurrentYTDDuration_jpcrp040300-q3r_E00935-000MedicineReportableSegmentsMember－JPY
Other incomeCurrentYTDDuration_jpcrp040300-q3r_E00935-000RealEstateReportableSegmentsMember1821000000JPY
Other incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1821000000JPY
Other incomeCurrentYTDDuration_ReconcilingItemsMember－JPY
Other incomeCurrentYTDDuration1821000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E00935-000MedicineReportableSegmentsMember52864000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E00935-000RealEstateReportableSegmentsMember1821000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember54685000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration54685000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E00935-000MedicineReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E00935-000RealEstateReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E00935-000MedicineReportableSegmentsMember52864000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E00935-000RealEstateReportableSegmentsMember1821000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember54685000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration54685000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E00935-000MedicineReportableSegmentsMember7858000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E00935-000RealEstateReportableSegmentsMember1015000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember8873000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember－JPY
Operating incomeCurrentYTDDuration8873000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-02-13
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第104期第３四半期(自　2023年10月１日　至　2023年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)科研製薬株式会社
Company name in english cover pageFilingDateInstantKAKEN PHARMACEUTICAL CO., LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　堀　内　裕　之

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass